Berlin startup Newsenselab closes new financing round for digital therapeutic against migraine

Berlin, Germany, December 20, 2021 – Berlin Startup Newsenselab is rounding out a year of successes with their most recent financing round. Headlining the list of achievements is “M-sense Migräne”, a digital health application (DiGA) eligible to be reimbursed by statutory health insurances in Germany. With the results of a randomised controlled trial the company is now aiming to prove the effectiveness of the migraine app. With these milestones reached, both existing and new investors participated enthusiastically in the financing round.

 

2021 has been a year of accomplishment for the Berlin-based startup Newsenselab GmbH. Their migraine app has completed its first year on the preliminary listing in the register of certified digital health apps, overseen by the ​​German Federal Institute for Drugs and Medical Devices (BfArM). The results are more than encouraging: not only is Newsenselab drawing a positive balance, but the startup can observe its impact on the medical treatment of migraines overall.

The digital health app “M-sense Migräne” has helped its users to manage over 100,000 headache attacks throughout the past year. Physicians trust the app’s functions to support them in their treatment of migraine patients and prescribe the digital health app with increasing frequency.

Seeking to fully prove the effectiveness of their digital health app, Newsenselab conducted the digital, decentralised RCT-trial EMMA this year as well. EMMA was the first clinical study on migraine to be conducted exclusively online, and sets the standard for digital clinical trials and digitized recruitment strategies. As of now, EMMA saw its last patient-out on December 6, and an independent scientific institution is now transitioning from the completion of the clinical evaluation to readying the publication of the results, which are to be expected early in 2022.

Newsenselab is thrilled to add to this successful year by announcing the closing of their most recent financing round. The round was led by Berlin’s IBB Ventures, Dutch impact investor Noaber and Munich based MedTech Entrepreneurs with participation of High-Tech Gründerfonds, Eternity.Health and business angel Dr. Klaus Hilleke. Law firm Dentons advised the company.

 

Newsenselab is excited to use this latest financing round to expand on its expertise in creating digital medicine for episodic chronic diseases.

 

 

Back